Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer—a study protocol for a randomised controlled trial

Abstract Background Distressing symptoms are common in advanced cancer. Medicinal cannabinoids are commonly prescribed for a variety of symptoms. There is little evidence to support their use for most indications in palliative care. This study aims to assess a 1:20 delta-9-tetrahydrocannabinol/canna...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Taylan Gurgenci, Janet Hardy, Georgie Huggett, Karyn Foster, Anita Pelecanos, Ristan Greer, Jennifer Philip, Alison Haywood, Ruwani Mendis, Patsy Yates, Phillip Good
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2024-05-01
Colecção:	Trials
Acesso em linha:	https://doi.org/10.1186/s13063-024-08091-z
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!